Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.48 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29794302 | 1.00 | CYP2C19 (0.52) | CYP2C19CYP2D6ESR1ESR2CA1 | |
| SCHEMBL14874462 | 0.88 | MMP8 (0.50) | CYP2C19CYP2D6CA1CA2ACHE | |
| SCHEMBL29794297 | 0.87 | CYP2D6 (0.51) | CYP2C19CYP2D6POLBHTTNPSR1 | |
| SCHEMBL467919 | 0.87 | CYP2D6 (0.51) | CYP2C19CYP2D6POLBHTTNPSR1 | |
| SCHEMBL28119493 | 0.86 | CYP2D6 (0.50) | CYP2C19CYP2D6ESR1ESR2CA1 | |
| SCHEMBL23256418 | 0.84 | EPHX1 (0.58) | CYP2C19CYP2D6POLBHTTNPSR1 | |
| SCHEMBL20060131 | 0.84 | ESR1 (0.49) | CYP2C19ESR1ESR2CA2POLB | |
| SCHEMBL684343 | 0.82 | ATM (0.48) | CYP2C19ESR1ESR2CA2POLB | |
| SCHEMBL23880085 | 0.81 | CTSD (0.47) | CA1CA2ACHEPOLBHTT | |
| SCHEMBL1234209 | 0.80 | ESR1 (0.68) | CYP2C19ESR1ESR2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | EyePoint Pharmaceuticals, Inc. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4101297-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | Aerpio Pharmaceuticals, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint, Inc. | 2022-09-01 | — | — | US | disclosed |
| CN-114939117-A | Method of treating vascular leak syndrome | 视点制药公司 | 2022-08-26 | — | — | CN | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | EyePoint Pharmaceuticals, Inc. | 2022-01-20 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | EyePoint Pharmaceuticals, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | EyePoint Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-20110253725-A1 | MULTI-PORT BEVERAGE AND FOOD CONTAINERS | KILLIAN WILLIAM | 2011-10-20 | — | — | US | disclosed |
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | EyePoint Pharmaceuticals, Inc. | 2011-09-01 | — | — | US | disclosed |
| WO-2011005330-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AKEBIA THERAPEUTICS INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005330-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR PREVENTING METASTASIS OF CANCER CELLS | AKEBIA THERAPEUTICS INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| US-7795444-B2 | Human protein tyrosine phosphatase inhibitors and methods of use | Warner Chilcott Company (US) | 2010-09-14 | — | — | US | disclosed |
| WO-2010081172-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AKEBIA THERAPEUTICS INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010081172-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | AKEBIA THERAPEUTICS INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2038265-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008002570-A2 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212951-A1 | HUMAN PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE | PTPRCAP, PTPRC, PPP5C | CYP2C19 4869/4885CYP2D6 4815/4885ESR1 4443/4885 |
| US-20220016086-A1 | COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASES | FLT4, VEGFA, AQP3 | CYP2C19 4320/4885CYP2D6 4838/4885ESR1 4354/4885 |
| US-20200277267-A1 | METHODS FOR TREATING VASCULAR LEAK SYNDROME | ICAM1, VCAM1, VIPR2 | CYP2C19 4287/4885CYP2D6 4067/4885ESR1 4686/4885 |
| US-20220274976-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | CYP2C19 4592/4885CYP2D6 4587/4885ESR1 4013/4885 |
| US-12152023-B2 | Compositions, formulations and methods for treating ocular diseases | TIE1, TEK, KDR | CYP2C19 4592/4885CYP2D6 4587/4885ESR1 4013/4885 |
| US-20200361926-A1 | COMPOSITIONS, FORMULATIONS AND METHODS FOR TREATING OCULAR DISEASES | TIE1, TEK, KDR | CYP2C19 4592/4885CYP2D6 4587/4885ESR1 4013/4885 |
| US-20080004267-A1 | Human protein tyrosine phosphatase inhibitors and methods of use | PTPRCAP, PTPRC, PPP5C | CYP2C19 4869/4885CYP2D6 4815/4885ESR1 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.